SummaryThe FDA issued a Class II recall for Sun Pharmaceutical's generic Vyvanse (lisdexamfetamine dimesylate capsules). The recall, started October 28, is due to failed dissolution specifications, meaning the drug may be less effective. Class II means health risk is low but temporary consequences are possible. Patients are advised to consult their doctor before stopping the medication.